At Vyriad, we are developing the next generation of targeted genetic therapies by engineering viruses, viral vectors and viral envelope glycoproteins to deliver genes directly to targeted cells. This targeting technology facilitates oncolytic virotherapy, in vivo gene therapies and gene editing applications. We are testing our oncolytic viruses as monotherapies and in combination with immuno-oncology drugs. Phase 1-2 Clinical Studies are currently active in: Non-small cell lung cancer Squamous cell carcinoma of the head and neck Metastatic colorectal cancer Breast cancer Bladder cancer Other cancer types Vyriad has clinical research collaboration agreements with Regeneron, Mayo Clinic, and other leading research and medical institutions.
View Top Employees from VyriadWebsite | http://www.vyriad.com/ |
Revenue | $14.8 million |
Funding | $53.9 million |
Employees | 46 (42 on RocketReach) |
Founded | 2015 |
Address | 2900 37th Street 110 NW Bldg, Rochester, Minnesota 55901, US |
Phone | (507) 289-0944 |
Technologies |
JavaScript,
HTML,
PHP
+16 more
(view full list)
|
Industry | Biotechnology, Business Services General, Drug Discovery, Business Services, Science and Engineering |
Competitors | BeyondSpring, G1 Therapeutics, Inc., Galera Therapeutics, Inc., GlycoMimetics, Otonomy, Inc |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 541714 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 5417 Companies |
Looking for a particular Vyriad employee's phone or email?
The Vyriad annual revenue was $14.8 million in 2024.
Kah-Whye Peng is the Co-founder, Chief Technical Officer of Vyriad.
42 people are employed at Vyriad.
Vyriad is based in Rochester, Minnesota.
The NAICS codes for Vyriad are [541714, 541, 54171, 54, 5417].
The SIC codes for Vyriad are [873, 87].